An Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of TST001 for Patients With CLDN18.2 Positive Previously Treated Unresectable Advanced or Metastatic Biliary Tract Cancer
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Osemitamab (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
Most Recent Events
- 25 Jul 2023 Status changed from recruiting to completed.
- 31 May 2022 Status changed from not yet recruiting to recruiting.
- 20 Jan 2022 New trial record